Bruker Corporation introduced iNTApharma at the Society for Laboratory Automation and Screening (SLAS) 2026 conference in Boston. The platform delivers label‑free, single‑particle sensitivity for measuring the size and concentration of viral vectors, extracellular vesicles, and lipid nanoparticles directly in native aqueous media.
iNTApharma employs interferometric scattering (iSCAT) detection, a technique developed at the Max‑Planck‑Institute for the Science of Light. The system covers bioparticles from 50 to 300 nm, provides results within minutes, and supports automated, well‑plate‑based acquisition that can run unattended in standard laboratory workflows.
The platform addresses a growing regulatory requirement for quality control in biopharma, where accurate particle size distribution and concentration are critical for process consistency and product safety. By enabling native‑state, unlabeled measurements, iNTApharma positions Bruker in the high‑growth mRNA drug‑delivery and gene‑therapy markets while complementing its existing spatial biology and mass‑spectrometry capabilities.
Early‑access partners will receive initial systems in the first half of 2026, with broader commercial availability slated for the second half of the year. Bruker’s President of the CALID Group, Jürgen Srega, said the platform “makes these capabilities broadly available and provides researchers with a tool that can deepen our understanding of nanoscale bioparticles.”
By adding iNTApharma, Bruker expands its portfolio into a rapidly expanding segment, potentially capturing a larger share of the post‑genomic instrumentation market. The native‑state, label‑free capability offers a competitive advantage over existing methods that require labeling or disrupt native conditions, thereby strengthening Bruker's position in the biopharma analytical space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.